Research Wrap-Up: CAHO Catalyst Fall 2015
“Without health research, you can’t have clinical trials, and without clinical trials, you can’t improve the health of Ontarians.” – Patient Gretta Hutton’s Mantle Cell Lymphoma is in remission, thanks to a clinical trial at Hamilton Health Sciences. Just one of many inspiring stories in this season’s Fall Catalyst.
The Fall Catalyst
CAHO’s Fall Catalyst has arrived with an inspiring collection of patient and research stories. From a world-first, collaborative cancer therapy trial, to a poignant patient interview on the importance of clinical trials, this issue taps into the many voices of Ontario’s health research enterprise to tell the story of why it matters to all of us. In the words of CAHO’s Chair, Catherine Zahn, “These voices remind us that research changes real lives, for the better, now.” We couldn’t agree more, and we hope that you enjoy and share these stories as part of the #onHWS conversation.
Not signed up for Catalyst? Register at the bottom of this page!
The Importance of Clinical Trials: A Conversation with Patient Gretta Hutton
In the spring of 2014, Gretta Hutton received a call from a physician while in a Home Depot parking lot. She was diagnosed with Mantle Cell Lymphoma and given 2 – 5 years to live. After weeks of feeling hopeless, both her sister and a friend told Gretta about a clinical trial at Hamilton Health Sciences led by Dr. Tom Kouroukis. One year later, with her cancer in full remission, Gretta sat down with Catalyst to talk about the importance of clinical trials for Ontario patients.
Ontario Researchers Lead the World’s First Clinical Trial of a Double Virus Therapy for Cancer Patients
Patients across Ontario research hospitals are taking part in the world’s first clinical trial of a new cancer-fighting double virus therapy discovered jointly by scientists at CHEO, The Ottawa Hospital, and McMaster University. Building on decades of scientific thought, this unique therapy attacks and kills cancer cells, while stimulating an anti-cancer immune response, demonstrating enormous potential for the future of cancer treatment.
Innovative Technology by MolecuLight Inc. Poised to Revolutionize Chronic Wound Care
Ontario healthcare innovator, MolecuLight Inc., is commercializing a hand-held optical imaging technology designed to visualize bacteria in real-time at the point-of-care. Founded by Dr. Ralph DaCosta, Scientist at The Princess Margaret Cancer Centre and Techna Institutute in partnership with University Health Network, MolecuLight’s device is revolutionizing wound care and strengthening Ontario’s role as a global innovation leader in health care.
Ontario Continues Growing as a Global Leader in Cancer Research
An estimated 188,000 Canadians will be diagnosed with cancer this year and as our population ages that number is expected to increase. Mount Sinai Hospital has attracted top international cancer researcher Dr. Daniel Schramek to fulfill the role of Kierans/Janigan Cancer Research Scientist at the Lunenfeld-Tanenbaum Research Institute, part of the Sinai Health System. One of his many contributions to the field is a new technique to weed out the random genetic bystander mutations while identifying those that are critical for cancer.
Ottawa Decision Tool Detects 100% of Subarachnoid Hemorrhage (SAH) Cases, Could Save Province $25 Million
With headache as its predominant symptom, subarachnoid hemorrhage (SAH) can be dangerously challenging to diagnose, with a 50% fatality rate for misdiagnosis. A clinical decision tool developed at The Ottawa Hospital decreases that number to 0% by detecting 100% of SAH cases. The Ottawa SAH rule introduces potential cost savings of $25 million through avoiding death and disability.
To learn more about the value of health research in building a healthier, wealthier, smarter Ontario, you can also read our Policy Platform.